529 related articles for article (PubMed ID: 1735618)
21. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
22. Modulation of natural killer activity by thymosin alpha 1 and interferon.
Favalli C; Jezzi T; Mastino A; Rinaldi-Garaci C; Riccardi C; Garaci E
Cancer Immunol Immunother; 1985; 20(3):189-92. PubMed ID: 3851698
[TBL] [Abstract][Full Text] [Related]
23. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
[TBL] [Abstract][Full Text] [Related]
24. Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type.
Kedar E; Ben-Aziz R; Epstein E; Leshem B
Cancer Immunol Immunother; 1989; 29(1):74-8. PubMed ID: 2785003
[TBL] [Abstract][Full Text] [Related]
25. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
26. Restoration of immunocyte functions by thymosin alpha1 in cyclophosphamide-induced immunodeficient mice.
Ohmori H; Kamo M; Yamakoshi K; Nitta MH; Hikida M; Kanayama N
Immunopharmacol Immunotoxicol; 2001 Feb; 23(1):75-82. PubMed ID: 11322651
[TBL] [Abstract][Full Text] [Related]
27. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.
Garaci E; Pica F; Rasi G; Favalli C
Int J Immunopharmacol; 2000 Dec; 22(12):1067-76. PubMed ID: 11137613
[TBL] [Abstract][Full Text] [Related]
28. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.
Ciolli V; Gabriele L; Sestili P; Varano F; Proietti E; Gresser I; Testa U; Montesoro E; Bulgarini D; Mariani G
J Exp Med; 1991 Feb; 173(2):313-22. PubMed ID: 1671080
[TBL] [Abstract][Full Text] [Related]
29. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells.
Shrivastava P; Singh SM; Singh N
J Biomed Sci; 2004; 11(5):623-30. PubMed ID: 15316138
[TBL] [Abstract][Full Text] [Related]
30. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12.
Le HN; Lee NC; Tsung K; Norton JA
J Immunol; 2001 Dec; 167(12):6765-72. PubMed ID: 11739491
[TBL] [Abstract][Full Text] [Related]
31. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery.
Silecchia G; Guarino E; Sinibaldi-Vallebona P; Pierimarchi P; Restuccia A; Spaziani E; Bernard P; Tuthill C; Garaci E; Rasi G
Cancer Immunol Immunother; 1999 Jul; 48(4):172-8. PubMed ID: 10431686
[TBL] [Abstract][Full Text] [Related]
33. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.
Mihalyo MA; Doody AD; McAleer JP; Nowak EC; Long M; Yang Y; Adler AJ
J Immunol; 2004 May; 172(9):5338-45. PubMed ID: 15100273
[TBL] [Abstract][Full Text] [Related]
34. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
35. Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholanthrene-induced primary tumor in autochthonous mice.
Hosokawa M; Yabiku T; Ikeda J; Sawamura Y; Okada F; Komatsumoto M; Tanabe T; Kobayashi H
Jpn J Cancer Res; 1988 Oct; 79(10):1147-54. PubMed ID: 3143703
[TBL] [Abstract][Full Text] [Related]
36. Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide.
Li L; Okino T; Kan N; Yamasaki S; Ichinose Y; Sugie T; Kanaoka S; Imamura M
Biotherapy; 1998; 11(4):223-8. PubMed ID: 9950097
[TBL] [Abstract][Full Text] [Related]
37. Combined effect of interleukin 2 and cyclophosphamide in therapy of mice with transitional cell carcinoma.
Ikemoto S; Kamizuru M; Wada S; Hayahara N; Nishio S; Kishimoto T; Maekawa M
Urology; 1992 Dec; 40(6):574-8. PubMed ID: 1466115
[TBL] [Abstract][Full Text] [Related]
38. Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma.
Wojas-Turek J; Szczygieł A; Kicielińska J; Rossowska J; Piasecki E; Pajtasz-Piasecka E
Int J Oncol; 2016 Feb; 48(2):493-505. PubMed ID: 26648160
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha.
Ohkura M; Fuchimoto S; Orita K
Jpn J Cancer Res; 1990 Oct; 81(10):1026-31. PubMed ID: 2121675
[TBL] [Abstract][Full Text] [Related]
40. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2.
Wigginton JM; Lee JK; Wiltrout TA; Alvord WG; Hixon JA; Subleski J; Back TC; Wiltrout RH
J Immunol; 2002 Oct; 169(8):4467-74. PubMed ID: 12370382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
